Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Grifols S.A. ADR (GRFS)

Grifols S.A. ADR (GRFS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Grifols: Q2 Earnings Snapshot

BARCELONA, Spain (AP) _ Grifols SA (GRFS) on Thursday reported earnings of $164.9 million in its second quarter.

GRFS : 15.39 (+6.51%)
GIKLY : 11.9400 (-0.83%)
Moving Average Crossover Alert: Grifols (GRFS)

Grifols (GRFS) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

GRFS : 15.39 (+6.51%)
Myasthenia Gravis Treatment Market Size, Share, Trends, Analysis and Forecast 2027

The report on Myasthenia Gravis Treatment provides the clients with a comprehensive analysis of crucial driving factors, consumer behavior, growth trends, product utilization, key player analysis, brand...

ARGX : 331.67 (+2.50%)
ALPMF : 17.2500 (+0.88%)
AVDL : 7.95 (-0.38%)
BAX : 83.61 (+0.47%)
GSK : 38.93 (-0.46%)
GRFS : 15.39 (+6.51%)
MTZPY : 18.6000 (-0.13%)
NVS : 83.48 (-1.07%)
RARX : 48.00 (-0.03%)
TKPYY : 16.5900 (-0.90%)
VRX.TO : 30.80 (-3.33%)
Grifols introduces HyperHEP B® (hepatitis B immune globulin [human]), a new formulation to treat patients exposed to hepatitis B

, /PRNewswire/ -- a leading global producer of plasma-derived medicines and provider of a variety of postexposure prophylaxis and IgG products for patients, today began commercializing HyperHEP B, a new...

GIKLY : 11.9400 (-0.83%)
GRF : 9.38 (+0.11%)
GRFS : 15.39 (+6.51%)
Grifols takes another step in the fight against Alzheimer's, partners with Ace to open first AMBAR® Center in Barcelona

- - , /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines with a history of more than 110 years contributing to improve the health...

GIKLY : 11.9400 (-0.83%)
GRF : 9.38 (+0.11%)
GRFS : 15.39 (+6.51%)
Grifols: Q1 Earnings Snapshot

BARCELONA, Spain (AP) _ Grifols SA (GRFS) on Tuesday reported earnings of $156.7 million in its first quarter.

GRFS : 15.39 (+6.51%)
GIKLY : 11.9400 (-0.83%)
Grifols and Andorran government will establish world-class immunology research hub to expand global knowledge of the immune system and develop therapeutics

, /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines with a history of more than 110 years contributing to improve the health and...

GIKLY : 11.9400 (-0.83%)
GRF : 9.38 (+0.11%)
GRFS : 15.39 (+6.51%)
Grifols Extends Commitment to World Federation of Hemophilia Humanitarian Aid Program to 2030

, /PRNewswire/ --Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived medicines with a track record of more than 100 years dedicated to enhancing people's...

GIKLY : 11.9400 (-0.83%)
GRF : 9.38 (+0.11%)
GRFS : 15.39 (+6.51%)
Grifols 2020 Annual Report on Form 20-F filed with the SEC on April 9, 2021

, /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF), (MCE: GRF.P) and (NASDAQ: GRFS) announced that it has filed its 2020 Annual Report on Form 20-F with the United States Securities and Exchange...

GRF : 9.38 (+0.11%)
GRFS : 15.39 (+6.51%)
Grifols announces topline data from NIAID Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune globulins as a treatment for hospitalized patients with COVID-19

, /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived medicines with a track record of more than 100 years dedicated to enhancing people's...

GIKLY : 11.9400 (-0.83%)
GRF : 9.38 (+0.11%)
GRFS : 15.39 (+6.51%)

Barchart Exclusives

Natural Gas- Higher Multi-Year Highs
Natural gas has been making higher lows over the past fifteen months. The energy commodity began making higher multi-year highs in June 2021. With the peak season for demand on the horizon, the price is trading above $5, a level not seen since February 2014. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar